Clesacostat is an investigational drug being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). It functions as a liver-targeted inhibitor of acetyl-CoA carboxylase, reducing fatty acid synthesis and liver fat accumulation. The drug is still under clinical development and is not yet approved for routine medical use. The directory classifies it as a unknown/inactive API with a synthetic source/manufacturing origin. Other names for this substance include Benzoic acid, 4-(6-methoxy-4-((1, 4, 6, 7-tetrahydro-1-(1-methylethyl)-7-oxospiro(5H-indazole-5, 4′-piperidin)-1′-yl)carbonyl)-2-pyridinyl)-, 4-(4-(1-Isopropyl-7-oxo-1, 4, 6, 7-tetrahydrospiro[indazole-5 and 4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid. Its PubChem CID is 57496611.
Clesacostat
| CAS No | 1370448-25-1 |
|---|---|
| Molecular Formula | C28H30N4O5 |
| Molecular Weight | 502.6 g/mol |
| Synonyms | 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Clesacostat is an investigational drug being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). It functions as a liver-targeted inhibitor of acetyl-CoA carboxylase, reducing fatty acid synthesis and liver fat accumulation.
The listed CAS number is 1370448-25-1.
The listed molecular formula is C28H30N4O5.
The listed molecular weight is 502.6 g/mol.
4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid.
The source lists Benzoic acid, 4-(6-methoxy-4-((1, 4, 6, 7-tetrahydro-1-(1-methylethyl)-7-oxospiro(5H-indazole-5, 4'-piperidin)-1'-yl)carbonyl)-2-pyridinyl)-, 4-(4-(1-Isopropyl-7-oxo-1, 4, 6, 7-tetrahydrospiro[indazole-5 and 4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid.